Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 STN1013900 plus latanoprost in primary open angle glaucoma or ocular hypertension
jRCT2031210122Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in open-angle glaucoma (OAG) and ocular hypertension comparing STN1013900 + latanoprost with Vehicle + latanoprost (2 arms). Primary endpoint: Mean diurnal intraocular pressure at Week 4. Started Jul 2021; status: completed.
02
Drugs
netarsudil
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCT2031210122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210122.